In recent years, the FDA has approved several new drugs for the management of a range of neurological diseases. This article briefs the molecules that have been approved and mentions their primary targets. 1. Meningococcal group B vaccine This vaccine aims to prevent invasive meningococcal pathologies induced by Neisseria meningitis serogroup B. The vaccine is primarily meant for individuals of 10-25 years of age. 2. The combination of carbidopa/levodopa The drug combination works by inhibiting the aromatic amino acid decarboxylation pathway.
Formulated as a suspension, this combination aims to treat Parkinson’s patients with motor fluctuations. 3. Carbidopa/levodopa extended release formulation This extended release combination therapy is designed against post-encephalitic parkinsonism and generalized PD. The drug must not be given to MAO recipients. 4. Diclofenac sodium injection…
